Generex Biotechnology Corporation

GNBT · OTC
Analyze with AI
7/31/2020
7/31/2019
7/31/2018
7/31/2017
Operating Activities
Net Income-$34,232-$11,007$35,949-$76,833
Dep. & Amort.$1,004$426$24$5
Deferred Tax$0$0$0$0
Stock-Based Comp.$0$0$0$0
Change in WC$10,085$11,076$762$994
Other Non-Cash$14,953-$13,076-$39,028$74,663
Operating Cash Flow-$6,121-$9,574-$2,293-$1,170
Investing Activities
PP&E Inv.-$5-$316-$9$0
Net Acquisitions$49$2,280$320$12
Inv. Purchases$0$0$0-$4,000
Inv. Sales/Matur.$0$0$0$4,000
Other Inv. Act.$0$355-$320$0
Investing Cash Flow$45$2,319-$9$12
Financing Activities
Debt Repay.$0$0$0$0
Stock Issued$110$2,000,000$0$3,000
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$5,810$6,508,726$454$4,036
Financing Cash Flow$5,810$6,509$454$4,036
Forex Effect-$17-$1$15-$16
Net Chg. in Cash-$283-$748-$1,833$2,862
Supplemental Information
Beg. Cash$298$1,046$2,879$17
End Cash$15$298$1,046$2,879
Free Cash Flow-$6,126-$9,891-$2,302-$1,170
Generex Biotechnology Corporation (GNBT) Financial Statements & Key Stats | AlphaPilot